Performance of each pharmaceutical company competing for joint promotion

A rare atmosphere was recently formed among domestic pharmaceutical companies which compete over introduction of blockbuster products.

In this process, a number of products were switched for companies to jointly promote; will there be any change in performance after the switchovers?

According to the data of UBIST for the 1^st quarter of 2016, 3 of 4 products introduced by Yuhan Corporation sho...